Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920307 | 0.84 | CMA1 (0.53) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL1920302 | 0.84 | CMA1 (0.53) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL733605 | 0.84 | CMA1 (0.53) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL1920304 | 0.84 | CMA1 (0.53) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL18205232 | 0.81 | SIGMAR1 (0.57) | CMA1SIGMAR1SMN1; SMN2KDM4EPTGIR | |
| SCHEMBL2916777 | 0.78 | DRD4 (0.57) | CMA1SIGMAR1SMN1; SMN2KDM4EPTGIR | |
| SCHEMBL2918073 | 0.78 | SIGMAR1 (0.57) | CMA1SIGMAR1SMN1; SMN2KDM4EPTGIR | |
| SCHEMBL19518531 | 0.78 | FUCA1 (0.55) | SIGMAR1 | |
| SCHEMBL30875889 | 0.78 | FUCA1 (0.55) | SIGMAR1 | |
| SCHEMBL20417932 | 0.78 | FUCA1 (0.55) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1615894-A2 | 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004089908-A2 | 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | CMA1 3507/4885SIGMAR1 68/4885SMN1; SMN2 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.